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Walton Oaks, UKA B S T R A C TObjectives: To describe a population with moderate rheumatoid
arthritis (RA) before biologic initiation and assess change in disease
status, health-related quality of life (HRQOL), and adverse events in
etanercept (ETN)-treated patients. Methods: Data on adult patients
with moderate RA (3.2o Disease Activity Score in 28 Joints [DAS28]r
5.1) were retrospectively analyzed from the British Society for Rheu-
matology Biologics Register comparing a nonbiologic-treated group
(nBG) using at least one traditional disease-modifying antirheumatic
drug to a biologic group (BG) treated with ETN. The HRQOL was
assessed by using the Health Assessment Questionnaire disability
index score. To mitigate confounding, we controlled for drivers of
progression. Appropriate univariate, multivariate, and regression
analyses were used. Results: A total of 1754 patients with RA were
assessed (211 BG and 1543 nBG). Compared with the nBG, the BG
tended toward higher disease activity, such as signiﬁcantly higher
tender joints and DAS28. The BG compared with the nBG had 1) a
greater reduction in DAS28 and Health Assessment Questionnaireee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.05.005
.Horowicz-Mehler@quintiles.com; nch2104@colum
ndence to: Nathalie Horowicz-Mehler, Quintiles Advscores; 2) disease remission occurring more often (odds ratio ¼ 2.7; P ¼
0.006); and 3) progression occurring in fewer patients (odds ratio ¼ 0.3;
P ¼ 0.002). BG patients had a higher incidence of “other serious
infection” and “other central nervous system–related events,” with
no signiﬁcant differences in associated hospitalization rates or
deaths. Conclusions: Among patients with moderate RA from a
clinical practice registry, ETN-treated patients had signiﬁcantly higher
disease activity at the time of biologic initiation but signiﬁcantly
reduced disease activity and better HRQOL after 6 months compared
with nBG patients, although the possibility of unmeasured confound-
ing remains. The ETN group reported signiﬁcantly higher incidences
of “other serious infections” and “other central nervous system–
related events” without higher hospitalization rates.
Keywords: etanercept, health-related quality of life, rheumatoid
arthritis, treatment comparison.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Historically, various immune-modulating agents have been used
in patients with rheumatoid arthritis (RA); however, one had to
be mindful of toxicities linked to idiosyncratic dosing of the
therapy either alone or in combination therapy. Several recently
completed randomized controlled trials demonstrate that an
early and aggressive approach to treatment has emerged as a
key intervention for controlling disease activity effectively and
achieving optimal results [1,2]. More than two-thirds of European
rheumatologists surveyed reported the presence of symptoms for
less than 3 months as “early” RA. These same surveyedrheumatologists said that 50% of their patients are referred after
6 months of disease [3]. RA may initially be treated with non-
pharmacologic or over-the-counter therapies, especially when
the diagnosis is still in question. Once a diagnosis is sus-
pected, primary care or other non-RA specialists may start with a
high-dose nonsteroidal anti-inﬂammatory drug and steroids.
Some may even begin one or more disease-modifying antirheu-
matic drug (DMARD) as they transition the patient to a specialist;
yet this is not always the case. A biologic response modiﬁer may
be recommended by the specialist if active disease and inﬂam-
mation persists despite high doses of one or more DMARDs,
particularly in the presence of prognostically unfavorable factorsociety for Pharmacoeconomics and Outcomes Research (ISPOR).
bia.edu.
isory Services, 60 East 42nd Street, Suite 2230, New York, NY 10165.
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etanercept, adalimumab, or inﬂiximab, are usually recom-
mended, along with methotrexate.
Previous work on the real-world burden of disease of patients
with RA highlighted low health-related quality of life (HRQOL) at
the time a decision is made to move past DMARDs onto biologic
therapy [5]. Previous studies have shown that early aggressive
management of RA has resulted in better clinical and radiographic
outcomes [6]. Yet, the impact of biologics on clinical and patient-
reported measures in patients with moderate RA remains unclear
because there is limited data available in this population. Despite
indications for treatment, the patient population with moderate
RA is often not considered when assessing the impact of biologic
therapy because of a perception of lower levels of disease burden.
The ﬁrst objective of this study was to explore the clinical
characteristics of patients with moderate RA, their real-world
pathway from one treatment to the next treatment, and treat-
ment outcomes through an analysis of longitudinal patient-level
registry data. Speciﬁcally, we aimed to assess, at the time of RA
therapy initiation, the baseline disease characteristics, socio-
demographic characteristics, initial treatment proﬁle, and quality
of life of two cohorts of patients with moderate RA, one newly
exposed to etanercept (Enbrel) and the other exposed to other
nonbiologic therapies. The second objective of this study was to
assess the change over time in disease characteristics, adverse
events (AEs), treatment patterns, treatment, quality-of-life out-
comes, and resource utilization within these two cohorts.
The National Institute for Health and Care Excellence guidance
[7] states that only those patients who achieve an improvement of
at least 2.1 points in the Disease Activity Score in 28 Joints (DAS28)
after 6 months of etanercept therapy can remain on etanercept;
thus, results pertaining to the 6-month follow-up will be empha-
sized in ﬁndings relative to 12- and 24-month ﬁndings.Methods
Patient Population
This was a nonexperimental, retrospective cohort study that used
anonymous UK patient-level data provided by the British Society
for Rheumatology Biologics Register (BSRBR) [8]. The BSRBR, estab-
lished in the United Kingdom in 2001, is a national prospective
observational study that enrolled patients with RA initiated on
biologic therapies (etanercept, inﬂiximab, or adalimumab), thereby
monitoring the long-term safety of biologic drugs and providing
valuable information about their long-term effects. Recruitment of
4000 patients with RA treated with each of the three biologic drugs,
along with 4000 biologic-naive patients with active RA receiving
standard DMARD therapy, was targeted at the start of the study [9].
This target for the etanercept cohort was met in 2005, for the
inﬂiximab cohort in 2007, and for the adalimumab cohort in 2008.
Before recruitment targets were achieved, it was estimated that
more than 80% of the patients with RA treated with biologics were
registered on the BSRBR out of the estimated 7% of the patients
with RA treated with biologics in the United Kingdom [10].
Baseline Data
A standard baseline questionnaire was completed by the con-
sultant or specialist nurse at enrollment for both biologic and
DMARD cohorts. The questionnaire collected data on demo-
graphic characteristics; the 1987 American College of Rheumatol-
ogy (ACR) criteria for RA; and clinical characteristics including
previous joint replacement or surgery, systemic features, and
components necessary to calculate the DAS28 (such as tender
joint count, swollen joint count, erythrocyte sedimentation rate,C-reactive protein, and patient global visual analogue scale [VAS]
score); details of all previous and current DMARD therapy;
and comorbidities including hypertension, angina, stroke, and
diabetes. The patients were also asked to complete a separate
questionnaire collecting data on smoking habits, occupational
history, as well as quality-of-life instruments such as the Health
Assessment Questionnaire (HAQ) for British use [11] and the
Medical Outcomes Study short-form 36 health survey (SF-36)
(assessed by Physical Component Summary [PCS] score, Mental
Component Summary [MCS] score, and vitality domain score).
Follow-Up Data
All patients with RA in both cohorts were followed for 5 years,
during which follow-up took place every 6 months for the ﬁrst 3
years and then annually for the next 2 years. At each follow-up
visit, the clinician completed a questionnaire documenting changes
to antirheumatic therapy, reasons for discontinuation, and current
DAS28-related evaluations. The follow-up questionnaire also incor-
porated details of AEs including whether the AE was related to the
biologic therapy and the outcome of the AE, such as hospitalization
or death. For the ﬁrst 3 years of the study, the patients completed a
diary every 6 months that incorporated information on any new
medical diagnoses/illness, new drugs, and hospital admissions.
Also, information was collected from patients regarding HAQ and
SF-36 questionnaires. Furthermore, all patients were ﬂagged with
the UK Ofﬁce for National Statistics, which provided information on
mortality including the cause of death [9].
Inclusion and Exclusion Criteria
From previously published BSRBR criteria [12], patients with
moderate RA as deﬁned by a DAS28 (43.2 and r5.1) and age 18
years and more at the time of diagnosis were eligible for inclusion
in the analysis. The study compared two groups: 1) The biologic
group (BG)—Patients with moderate RA newly starting therapy
with a biologic (etanercept/Enbrel). These patients may or may
not be treated with nonbiologic DMARDs before initiating treat-
ment with etanercept for RA. 2) The nonbiologic group (nBG)—
Patients were selected if they had moderate RA, were receiving a
DMARD, had no history of exposure to biologic therapies, and
were felt to have moderately active disease. New use of a
nonbiologic DMARD was not required for comparator patients.
Statistical Analyses
All study subjects with moderate RA satisfying the inclusion/
exclusion criteria were considered for analysis. For postbaseline
treatment comparisons of the BG and the nBG, intent-to-treat
analysis was performed in which the treatment assigned at the
baseline was used irrespective of the treatment received during
the observational period.
Baseline sociodemographic characteristics, disease character-
istics, initial treatment proﬁle, baseline DAS28-related evalua-
tions, and HRQOL were compared between the BG and nBG
patients. Continuous variables were compared using the two-
sample t test, whereas categorical variables were evaluated using
the chi-square test or the Fisher exact test as appropriate.
Change in DAS28-related evaluations and HRQOL from base-
line to 6-, 12-, and 24- month follow-up visits was evaluated
using analysis of covariance between the BG and nBG patients.
Assessment of change in DMARD therapy and development of
AEs at 6-, 12-, and 24-month follow-up visits between the two
groups was carried out using the chi-square test or the Fisher
exact test as appropriate.
Improvement in RA deﬁned by ACR criteria (ACR20 Z20%
improvement in tender joint count, Z20% improvement in
swollen joint count, and Z20% improvement in three of the
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index score, erythrocyte sedimentation rate, and C-reactive
protein) at follow-up visits was analyzed by using the chi-
square test or the Fisher exact test as appropriate. Improvement
in RA was also assessed by European League Against Rheuma-
tism (EULAR) response categories, which provided a qualitative
assessment of the progression of disease (EULAR criteria for Good
response: Follow-up DAS28 of o3.2 and an improvement of 41.2
in DAS28 after starting therapy) using multivariate logistic
regression. Disease remission (DAS28 o 2.6) between BG and
nBG group patients was analyzed by using the Cochran-Mantel-
Haenszel test [13].
The baseline covariates used in the multivariate analyses
included age, sex, race, occupation, smoking status, disease
duration, time since ﬁrst rheumatologist visit, body mass index,
previous number of DMARDs, diabetes, hyperthyroidism, high
blood pressure, angina, heart attack, stroke, chronic obstructive
pulmonary disease, prior tuberculosis, asthma, peptic ulcer, liver
disease, renal disease, central nervous system-demyelination,
epilepsy, depression, and past malignancy.
Because data for DAS28-related evaluations (e.g., tender joint
count, swollen joint count, erythrocyte sedimentation rate, C-
reactive protein, patient global VAS score, and DAS28) had
arbitrary missing patterns at baseline and follow-up visits at 6,
12, and 24 months, missing data were imputed by applying
multiple imputation analyses using the Markov Chain Monte-
Carlo method (number of repeated imputations ¼ 5) [14]. The
following baseline variables were included in the imputation
analyses: age, sex, occupational status, smoker/nonsmoker, dis-
ease duration, body mass index, chest x-ray performed, ACR
criteria, systemic features, current use of DMARDs, number of
comorbidities, HAQ disability index score, individual DAS28-
related evaluations, SF-36 PCS score, MCS score, and vitality
domain score. The data were normalized using Box-Cox or PowerTable 1 – Baseline characteristics.
Characteristic nBG (N ¼ 1
Sex: female, n (%) 1098 (71.
Age (y) 60.6  0
Unemployed due to disability, n (%) 207 (16.0
Current smoker, n (%) 350 (22.8
Disease duration (y) 10.2  0
Time since ﬁrst rheumatologist visit (y) 9.7  0.
Systolic BP 138.0  0
Prior chest x-ray, n (%) 742 (51.5
History of angina, n (%) 115 (7.5
Chronic bronchitis/emphysema, n (%) 124 (8.1
Hyperthyroidism, n (%) 65 (4.2)
Cancer, n (%) 102 (6.6
Tender joint count (range 0–28) 4.8  0.
Swollen joint count (range 0–28) 3.7  0.
ESR (mm/h) 25.9  0
CRP (mg/L) 25.0  1
Patient global VAS score 46.6  0
DAS28 total (range 0–10) 4.4  0.0
HAQ disability index score (range 0–3) 1.5  0.0
SF-36 PCS score 29.8  0
SF-36 MCS score 49.2  0
SF-36 vitality score 49.0  0
Note. Values are mean  standard error unless otherwise speciﬁed.
BG, biologic group; BP, blood pressure; CRP, C-reactive protein; DAS28, Dis
HAQ, Health Assessment Questionnaire; MCS, Mental Component Summ
36, short-form 36 health survey; VAS, visual analogue scale.transformations for variables that were heavily skewed or devi-
ating from the normal distribution. Statistical signiﬁcance was
deﬁned as P o 0.05 in the multivariate model. All analyses were
carried out using SAS (v9.2) (SAS Institute, Cary, NC).Results
Baseline Characteristics
A total of 1754 patients satisﬁed the inclusion/exclusion criteria
and were included in the analyses. Of these, 211 (12%) started
therapy with etanercept (BG), whereas 1543 (88%) were on therapy
with at least one traditional DMARD (nBG) at the time of inclusion.
Baseline characteristics of the patients are presented in Table 1.
The mean age of the patients with RA was 59.8 (standard error 0.3)
years, with BG patients being younger than nBG patients. nBG
patients were signiﬁcantly less likely to be unemployed because
of disability (33% vs. 16%), but were more likely to smoke than BG
patients. Patients had RA for an average of 10.7 years, with BG
patients displaying a longer disease duration than did nBG
patients, along with a longer duration since the ﬁrst rheumatol-
ogist visit. There was no difference in diastolic blood pressure
between the two groups; however, nBG patients had a higher
systolic blood pressure than did BG patients. Also, a signiﬁcantly
higher proportion of BG patients had a chest x-ray done before
new therapy as compared with nBG patients.
Comorbid conditions were observed in more than 50% of the
patients with RA, distributed similarly among both groups,
although history of angina, cancer, hyperthyroidism, and chronic
bronchitis was more common among nBG patients. BG patients
had more severe RA at baseline, demonstrated with higher
disease activity, tender joint count (mean  standard error 6.1
 0.3 vs. 4.8  0.1), swollen joint count (6.0  0.4 vs. 3.7  0.1), and543) BG (N ¼ 211) P
2) 163 (77.3) 0.065
.3 53.5  0.9 o0.001
) 59 (33.0) o0.001
) 37 (17.8) 0.007
.3 14.1  0.7 o0.001
3 13.1  0.7 o0.001
.5 134.3  1.4 0.016
) 183 (94.3) o0.001
) 5 (2.4) 0.006
) 8 (3.8) 0.027
3 (1.4) 0.048
) 6 (2.9) 0.033
1 6.1  0.3 o0.001
1 6.0  0.4 o0.001
.5 23.9  1.3 0.147
.6 26.7  2.5 0.593
.6 48.9  1.7 0.149
1 4.6  0.03 o0.001
4 1.9  0.07 o0.001
.2 27.3  0.5 o0.001
.2 49.1  0.6 0.886
.2 49.2  0.5 0.680
ease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate;
ary; nBG, nonbiologic group; PCS, Physical Component Summary; SF-
Table 2 – Baseline disease characteristics.
Characteristic nBG (N ¼ 1543) BG (N ¼ 211) P
ACR criteria, n (%)
Morning stiffness 4 1 h 1316 (85.4) 194 (91.9) 0.010
Arthritis or deformity of three or more joint areas 1133 (73.5) 179 (84.8) o0.001
Symmetry 978 (63.5) 175 (82.9) o0.001
Nodules 470 (30.5) 91 (43.1) o0.001
Erosions on hand or feet x-ray 730 (47.4) 116 (55.0) 0.038
Systemic features, n (%)
Sicca syndrome 166 (10.8) 45 (21.3) o0.001
Serosal involvement 18 (1.2) 7 (3.3) 0.024
Systemic vasculitis 14 (0.9) 6 (2.8) 0.026
Joint replacement/surgery, n (%)
Total knee replacement 141 (9.2) 31 (14.7) o0.001
Total hip replacement 99 (6.4) 29 (13.7) o0.001
Total shoulder replacement 24 (1.6) 21 (10.0) o0.001
Total elbow replacement 31 (2.1) 14 (6.6) o0.001
Wrist/hand/ankle/foot surgery 262 (17.0) 56 (26.5) 0.001
Neck surgery 9 (0.6) 9 (4.3) o0.001
ACR, American College of Rheumatology; BG, biologic group; nBG, nonbiologic group.
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Similarly, BG patients had a higher level of disability as measured
by mean HAQ disability index score (1.9  0.07 vs. 1.5  0.04) and
lower HRQOL as measured by SF-36 summary scores (PCS score
27.3  0.5 vs. 29.8  0.2). Furthermore, a higher proportion of BG
patients fulﬁlled the ACR criteria for RA diagnosis, had systemic
features, and had received joint replacement/surgery at baseline
than did nBG patients (Table 2).
Overall, BG and nBG patients had a similar initial proﬁle for
current RA therapy except for methotrexate and sulphasalazine,
whereas the nBG had a higher proportion of patients initially
treated with methotrexate and sulphasalazine. Previous use of
DMARDs was found to be more common in BG patients than in
nBG patients (Table 3).
Follow-Up Results
No difference was found between the proportion of patients having
a change in DMARD therapy between the two groups at 6 and 12
months, but a signiﬁcantly higher proportion of nBG patients
had a change in DMARD therapy at 24 months (13.3% vs. 5.3%).
Among patients who discontinued DMARD therapy, there was noTable 3 – Initial treatment proﬁle.
Disease characteristic nBG (N ¼ 1543)
Current DMARDs, n (%)
Methotrexate 963 (62.4)
Azathioprine 32 (2.1)
Cyclophosphamide 2 (0.1)
Cyclosporine 27 (1.7)
Leﬂunomide 158 (10.2)
Sulphasalazine 370 (24.0)
Previous DMARDs, n (%)
Methotrexate 1158 (75.0)
Azathioprine 118 (7.6)
Cyclophosphamide 7 (0.5)
Cyclosporine 70 (4.5)
Leﬂunomide 209 (13.5)
BG, biologic group; DMARD, disease-modifying antirheumatic drug; nBGsigniﬁcant difference in the duration to discontinuation between
the groups at any of the follow-up points. AEs were the most
common reason for the discontinuation of DMARD therapy, and
were more prevalent among nBG patients than among BG patients
(58.3% vs. 18.5% at 6 months and 66.7% vs. 11.1% at 12 months).
The overall DAS28 was found to be signiﬁcantly different
between the two groups at 6 months and 12 months, with BG
patients having a lower score as compared with nBG patients.
From univariate analysis, a greater reduction in DAS28 from
baseline was found among BG patients than among nBG patients
across all follow-up periods. Similar results were found after
adjusting for baseline differences. The reduction in DAS28 from
baseline was found to be signiﬁcantly higher among BG patients
than among nBG patients at 6 months (–0.93  0.10 vs. –0.29 
0.07), 12 months (–1.08  0.10 vs. –0.44  0.05), and 24 months
(–1.08  0.12 vs. –0.59  0.04) (Tables 4 and 5).
We found signiﬁcant differences in individual DAS28-related
evaluations between the two groups across all follow-up periods.
Unadjusted change in scores from baseline was found to be
signiﬁcant across individual DAS28-related evaluations between
BG and nBG patients for swollen joint count at 12 months and
tender joint count and patient global VAS score at 24 months.BG (N ¼ 211) P
65 (30.8) o0.001
7 (3.3) 0.313
0 1.000
0 0.066
14 (6.6) 0.099
20 (9.5) o0.001
198 (93.8) o0.001
61 (28.9) o0.001
10 (4.7) o0.001
40 (19.0) o0.001
111 (52.6) o0.001
, nonbiologic group.
Table 4 – Change in current DAS28-related evaluations and HRQOL from baseline at different follow-up periods
(unadjusted analyses).
Outcome 6 mo 12 mo 24 mo
nBG
(N ¼ 1543)
BG
(N ¼ 211)
nBG
(N ¼ 1543)
BG
(N ¼ 211)
nBG
(N ¼ 1543)
BG
(N ¼ 211)
DAS28-related evaluations
Tender joint count –0.27  1.28 –1.95  0.43 –0.92  1.52 –3.05  0.45 –0.56  0.54 –2.78  0.49
Swollen joint count 0.96  1.28 –2.60  0.41 0.26  0.58 –3.26  0.45 –0.77  0.78 –3.02  0.60
ESR 5.53  4.24 –2.71  1.48 2.36  4.84 –2.48  1.52 –0.86  2.24 –2.02  2.02
CRP –4.84  12.62 –14.25  2.52 –15.79  2.30 –12.75  3.24 –12.90  5.21 –12.95  4.17
Patient global VAS score –1.64  7.15 –12.72  2.34 8.13  8.65 –12.36  2.67 7.19  1.76 –9.19  2.46
DAS28 total –0.29  0.07 –0.92  0.09 –0.43  0.05 –1.14  0.10 –0.59  0.04 –1.10  0.14
HRQOL
HAQ disability index –0.01  0.01 –0.26  0.04 –0.00  0.02 –0.23  0.05 0.02  0.02 –0.18  0.05
SF-36 PCS score 0.16  0.20 1.99  0.67 –0.02  0.21 2.07  0.56 –0.25  0.25 1.47  0.65
SF-36 MCS score –0.40  0.22 –0.05  0.69 0.09  0.23 0.04  0.63 –0.17  0.26 0.88  0.61
SF-36 vitality score 0.08  0.22 –0.98  0.77 0.15  0.23 –1.09  0.64 0.20  0.27 –0.72  0.73
Note. Values are mean  standard error.
BG, biologic group; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; HRQOL, health-related quality of life; MCS, Mental Component Summary; nBG, nonbiologic group; PCS, Physical
Component Summary; SF-36, short-form 36 health survey; VAS, visual analogue scale.
* P o 0.05.
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baseline differences, there was no difference between the groups
except change in patient global VAS score at 24 months (BG vs.
nBG: –8.1  2.8 vs. 7.0  1.7; P ¼ 0.002) (Tables 4 and 5). It is pos-
sible that the imputation method based on baseline demo-
graphic characteristics as predictors of the DAS28 value biased
the results to the null, thus affecting the interpretability of
signiﬁcance levels for DAS28-related evaluations with high levels
of missing data.Table 5 – Change in current DAS28-related evaluations an
(adjusted analyses).
Outcome 6 mo
nBG
(N ¼ 1543)
BG
(N ¼ 211) (N
DAS28-related evaluations
Tender joint count –0.36  1.30 –1.25  0.53 –
Swollen joint count 0.74  1.29 –1.01  0.39
ESR 5.78  4.24 –4.55  2.17
CRP –4.90  12.49 –13.79  2.52 –1
Patient global VAS score –1.73  7.10 –12.07  2.26
DAS28 total –0.29  0.07 –0.93  0.10 –
HRQOL
HAQ disability index 0.08  0.09 –0.14  0.10
SF-36 PCS score –0.34  1.33 0.49  1.40 –
SF-36 MCS score –1.21  1.35 –0.70  1.42 –
SF-36 vitality score 1.70  1.33 1.84  1.39
Note. Analyses adjusted for age, sex, race, occupation, smoking status, dis
previous number of disease-modifying antirheumatic drugs received,
pressure, and angina mentioned above. Values are mean  standard err
BG, biologic group; CRP, C-reactive protein; DAS28, Disease Activity Sc
Assessment Questionnaire; HRQOL, health-related quality of life; MCS, M
Component Summary; SF-36, short-form 36 health survey; VAS, visual a
* P o 0.05.The level of disability as determined by the HAQ disability
index score was higher in BG patients than in nBG patients across
all follow-up periods; however, the decrease in the HAQ disability
index score was signiﬁcantly greater among BG patients than
among nBG patients. Results of adjusted analyses for the HAQ
disability index score were consistent with ﬁndings from unad-
justed analyses, in which the decrease in the HAQ disability
index score was found to be greater among BG patients at 6
months (–0.14  0.10 vs. 0.08  0.09), 12 months (–0.04  0.11 vs.d HRQOL from baseline at different follow-up periods
12 mo 24 mo
nBG
¼ 1543)
BG
(N ¼ 211)
nBG
(N ¼ 1543)
BG
(N ¼ 211)
1.05  1.55 –2.16  0.39 –0.68  0.52 –1.89  0.49
0.01  0.57 –1.41  0.41 –1.01  0.77 –1.23  0.41
2.83  4.95 –5.93  2.15 –0.45  2.33 –5.02  3.21
5.86  2.20 –12.25  1.78 –12.37  5.46 –16.83  3.54
8.02  8.62 –11.57  2.48 7.04  1.69 –8.09  2.78
0.44  0.05 –1.08  0.10 –0.59  0.04 –1.08  0.12
0.15  0.10 –0.04  0.11 –0.04  0.13 –0.19  0.13
1.55  1.31 –0.76  1.34 –1.37  1.72 –1.13  1.76
0.48  1.34 0.13  1.37 2.09  1.63 3.01  1.67
1.02  1.33 1.30  1.36 0.54  1.60 0.76  1.65
ease duration, time since ﬁrst rheumatologist visit, body mass index,
and comorbidities such as diabetes, hyperthyroidism, high blood
or.
ore in 28 Joints; ESR, erythrocyte sedimentation rate; HAQ, Health
ental Component Summary; nBG, nonbiologic group; PCS, Physical
nalogue scale.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 1 7 – 8 2 38220.15  0.10), and 24 months (–0.19  0.13 vs. –0.04  0.13). Results
from SF-36 showed a signiﬁcant improvement in the PCS score in
BG patients as opposed to nBG patients, but on controlling for
covariates, the groups did not differ from each other. Also, there
was no difference between SF-36 MCS and vitality domain scores
between the groups (Tables 4 and 5).
On evaluating AEs, it was found that BG patients had a greater
incidence of AEs than nBG patients at 6-month follow-up (11.5%
vs. 6.9), especially “other serious infection” and “other central
nervous system–related events.” The increased rate among BG
patients, however, was not associated with higher hospitalization
and death rates because there were no differences in these rates
between the two groups.
A signiﬁcantly higher proportion of BG patients achieved ACR20,
ACR50, and ACR70 criteria for improvement in RA over time than
did nBG patients. Furthermore, BG patients were more likely to be
categorized as “Good” responders and “Moderate” responders
according to the criteria set by EULAR. Also, BG patients were more
likely than nBG patients to achieve disease remission at all follow-
up periods. Moreover, disease progression occurred in fewer
patients in the BG group than in the nBG group (Table 6).
Of note, we did not have sufﬁcient power to detect differences
in all outcomes; however, we did have enough power to detect
most of the observed differences. We had more power to detect
differences in continuous variables (e.g., age and DAS28) than to
detect differences in proportions.Discussion
In summary, the vast majority (88%) of patients with moderate
RA in our study did not initiate etanercept but rather maintained
or initiated traditional DMARD therapy. On comparing both
groups at baseline, despite some similarities in the sociodemo-
graphic proﬁle, we found notable differences between BG and
nBG patients, including younger age (53.5  0.9 vs. 60.6  0.3
years) and a longer duration since the ﬁrst rheumatologist visit
(13.1  0.7 vs. 9.7  0.3 years). BG patients had more severeTable 6 – RA disease status at different follow-up period
Outcome 6 mo
nBG
(N ¼ 1543)
BG
(N ¼ 2
ACR categories
ACR20 13 (1.7) 18 (14.3
ACR50 2 (0.3) 7 (5.6)
ACR70 0 3 (2.4)
EULAR response
Good 331 (21.5) 74 (35.1
Moderate 276 (17.9) 45 (21.
None 936 (60.7) 92 (43.6
Disease status
Disease remission (DAS28 o 2.6) 207 (13.4) 47 (22.4
Low disease activity (2.6 r DAS28 r 3.2) 195 (12.6) 32 (15.2
No change (3.2 o DAS28 r 5.1) 819 (53.1) 103 (49.
Disease progression (DAS28 4 5.1) 322 (20.9) 28 (13.3
Note. Analyses for ACR categories and EULAR response were adjusted fo
since ﬁrst rheumatologist visit, body mass index, previous number of
such as diabetes, hyperthyroidism, high blood pressure, and angina me
ACR, American College of Rheumatology; BG, biologic group; DAS28, D
Rheumatism; nBG, nonbiologic group; RA, rheumatoid arthritis.
* P o 0.05.disease activity at baseline (DAS28 4.6  0.03 vs. 4.4  0.01) as
well as higher functional impairment as measured by mean HAQ
disability index score (1.9  0.07 vs. 1.5  0.04) and lower HRQOL
as measured by the SF-36 PCS score (27.3  0.5 vs. 29.8  0.2).
Furthermore, a higher proportion of BG patients received joint
replacement/surgery (Table 2) at baseline and were signiﬁcantly
less likely to be unemployed due to disability (33% vs. 16%).
Maybe not surprisingly, although they had greater disease activ-
ity and functional impairment at baseline, BG patients achieved
greater absolute changes in these measures over the 2-year study
period than did nBG patients whose improvement never reached
signiﬁcance. Indeed, BG patients exhibited a signiﬁcant change
from baseline to 6 months for DAS28 and HAQ, and these
improvements were maintained at 2 years. The results at
follow-up may have been affected by differences in baseline
characteristics between the two treatment groups; however, we
adjusted for baseline variables in the analysis and also controlled
for the outcome variable at baseline, which may have mitigated
the effect of these differences on follow-up results.
Current EULAR recommendations identify remission and low
disease activity as treatment targets and state that a change in
the therapeutic approach should be considered if treatment
targets are not met within 3 to 6 months [5]. In our study, only
13% of DMARD-treated nBG patients achieved DAS28 remission
within 6 months (vs. BG 22%), and 21% progressed to a severe
state (DAS28 4 5.1) within this time period (vs. 13% BG),
suggesting that BG patients with moderate RA, especially those
with “prognostically unfavorable factors” (e.g., presence of ero-
sions) could have beneﬁted from a change in or intensiﬁcation of
therapy, speciﬁcally the addition of a biologic such as etanercept.
Limitations include the fact that baseline characteristics
might reﬂect channeling bias such that older patients with
greater comorbidity were channeled away from etanercept and
those with greater disease activity were channeled toward
etanercept. When looking at other published BSRBR studies [15],
a lower proportion of etanercept-treated BG patients were treated
in combination with methotrexate (30%) than with other bio-
logics (adalimumab 40% and inﬂiximab 85%). This again mights.
12 mo 24 mo
11)
nBG
(N ¼ 1543)
BG
(N ¼ 211)
nBG
(N ¼ 1543)
BG
(N ¼ 211)
) 13 (1.9) 17 (15.5) 15 (2.7) 10 (9.8)
 3 (0.4) 3 (2.7) 4 (0.7) 3 (2.9)
 0 2 (1.8) 1 (0.2) 3 (2.9)
) 397 (25.7) 85 (40.3) 461 (29.9) 88 (41.7)
3) 314 (20.3) 59 (28.0) 316 (20.5) 47 (22.3)
) 832 (53.9) 67 (31.8) 766 (49.6) 76 (36.0)
) 261 (16.9) 56 (26.5) 313 (20.3) 58 (27.5)
) 206 (13.4) 37 (17.5) 234 (15.2) 41 (19.4)
0) 791 (51.3) 96 (45.5) 738 (47.8) 85 (40.3)
) 285 (18.5) 22 (10.4) 258 (16.7) 27 (12.8)
r age, sex, race, occupation, smoking status, disease duration, time
disease-modifying antirheumatic drugs received, and comorbidities
ntioned above.
isease Activity Score in 28 Joints; EULAR, European League Against
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 1 7 – 8 2 3 823reﬂect the channeling bias of methotrexate-intolerant patients
onto etanercept monotherapy, and one would expect greater
treatment effectiveness for combination versus monotherapy.
Second, the National Institute for Health and Care Excellence
guidance [16] states that only those patients who achieve an
improvement of at least 2.1 points in DAS28 after 6 months of
etanercept therapy can remain on etanercept; thus, greater
efﬁcacy would be expected in the BG group versus the nBG group.
Although the NICE guidance recommends etanercept for
patients with a DAS28 of more than 5.1, the average DAS28 for
the BG cohort was 4.6  0.03. Those patients with DAS28 below
the NICE threshold may have been considered an “at-need”
population, potentially due to a higher number of nodules at
baseline, erosions on hand or feet x-ray, or rates of joint replace-
ment. Third, DAS28 excludes assessment of hips, ankles, and feet;
thus, any disease to the lower limbs in our population cannot be
discussed. BG patients, however, had higher rates of wrist/hand/
ankle/foot surgery at baseline than nBG patients (26.5% vs. 17%),
and this difference could potentially have affected the decision to
initiate a biologic. Finally, the nBG group includes patients who
have initiated DMARD as well as prevalent traditional DMARD
therapy patients. As one moves away from the time of initiation
of therapy, one is less likely to observe a change in disease activity
and other clinical outcomes in the follow-up period.Acknowledgments
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